SIRT2 and cholangiocarcinoma: Experiments by Xu et al. [57] clearly demonstrated that SIRT2/c-MYC provides antioxidants to tumor cells, reduces intracellular mitochondrial oxidative phosphorylation levels, increases glucose-to-serine conversion, and ultimately promotes the proliferation of CCA cells via the downstream targets PHDA1 and serine synthesis pathways.